Arena Pharma (ARNA) Tops Q3 EPS by 2c; Issues Corp., R&D, BELVIQ Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. LEVI
3. SBUX
4. NVDA
5. GOOGL
6. AAPL
7. SPY
8. APLD
9. ORCL
10. USO

Go back to Arena Pharma (ARNA) Tops Q3 EPS by 2c; Issues Corp., R&D, BELVIQ Updates

RBC Capital Slashes PT on Arena Pharma (ARNA) to $2 Following Q3 Report, Update

November 11, 2015 8:53 AM EST

RBC Capital cuts its price target on Sector Perform-rated Arena Pharma (Nasdaq: ARNA) from $5 to $2 following Q3 results issued Tuesday night.

Analyst Simos Simeonidis commented, Arena reported 3Q15 earnings and provided additional color on the recently announced changes in strategic focus, following... More

Needham & Company Updates Ests on Arena Pharma (ARNA) Following Q3 Results; Maintains 'Hold' Rating

November 11, 2015 6:55 AM EST

Needham & Company affirms Arena Pharma (Nasdaq: ARNA) at Hold following the company's Q3 reprot on Tuesday night.

Analyst Alan Carr summarized: The company reported $4.9M in 3Q15 Belviq revenue from collaborators Eisai and Ildong, compared to our $4.7M estimate. Eisai... More